Back to List View Graph View

c-Met

c-Met, also known as the cellular mesenchymal–epithelial transition factor (c-MET), is a membrane protein and an established target in cancer research.

Where the papers sit

10 papers from the last 6 months study c-Met directly · updated from PubMed 11 Nov 2026

  • Targeted Drug Delivery in Cancer

    c-MET-directed treatment is moving toward bispecific antibodies, drug-conjugated aptamers and targeted protein degradation rather than receptor inhibition alone. In colorectal cancer, EGFR, c-MET and B7H3 co-expression is being used to guide dual-drug conjugates, while EMB-01 tests combined EGFR/c-MET blockade in heavily pretreated disease. Aptamer conjugates emphasize rapid tumor accumulation, payload release and improved endosomal escape. c-MET immunohistochemistry lacks prognostic value in early classic Hodgkin lymphoma, underscoring the need to match biomarkers to therapeutic selection.

    5 papers · 50%

  • Apoptosis-Based Liver Cancer Therapy

    Small-molecule development is targeting liver cancer through VEGFR-2 inhibition and combined c-MET/STAT3 blockade. Scaffold optimization and structure-activity studies prioritize potency alongside cell-cycle disruption and apoptosis. Recurrent BAX and BCL2 signals support mitochondrial apoptotic mechanisms as a key pharmacologic endpoint. The work remains preclinical, with in vitro activity and molecular design guiding compounds that still require validation in vivo.

    3 papers · 30%

  • Immune Escape in Squamous Cancer

    c-MET inhibition with tepotinib is linked to PD-L1 upregulation and an immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma. Spatial heterogeneity of PD-L1 and c-MET expression also appears in oral squamous cell carcinoma. These findings make baseline and spatial immune profiling important when considering c-MET-directed therapy. Whether combining c-MET inhibition with PD-1 or PD-L1 blockade can overcome the resulting immune suppression remains open.

    2 papers · 20%

NEW DIRECTION

c-Met can serve as a tumor-cell delivery receptor for cytotoxic payloads rather than solely as a signaling target

The c-Met-targeting aptamer–drug conjugate in multiple c-Met-overexpressing tumor models used receptor-mediated internalization to deliver MMAE and produce cytotoxicity that was explicitly independent of MET mutation status, whereas the other studies chiefly treat c-Met as a signaling target, biomarker, or therapeutic-binding site. This reframes c-Met overexpression as an address for selective payload delivery, potentially extending treatment beyond tumors in which c-Met inhibition itself is effective 42679803Sep.

Papers

The 10 papers from the last 6 months that study c-Met directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Targeted Drug Delivery in Cancer (5)
  1. Optimizing Endosomal Escape for Effective Aptamer-Based Ubiquitin-Mediated Degradation of c-Met. ACS applied materials & interfaces · 18 Oct 2026 PMID 42891827
  2. Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial. PloS one · 8 Oct 2026 PMID 42848781
  3. Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer. The journal of pathology. Clinical research · 30 Sept 2026 PMID 42811483
  4. Fast tumor accumulation and payload release of c-Met targeting aptamer-drug conjugate enables robust anti-tumor efficacy. Cell reports. Medicine · 1 Sept 2026 PMID 42679803
  5. EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 24 Aug 2026 PMID 42635595
Apoptosis-Based Liver Cancer Therapy (3)
  1. Thieno[2,3-d]pyrimidine scaffold optimization for synergistic c-Met/STAT3 blockade: Synthesis, structure-activity relationships, in vitro potency, and apoptotic pathways in colorectal cancer. Bioorganic chemistry · 21 Sept 2026 PMID 42767173
  2. New indolin-2-one and isoindoline-1,3-dione derivatives as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro, in vivo, and in silico evaluation. Bioorganic chemistry · 13 Jul 2026 PMID 42442295
  3. Design, synthesis, and bioactivity assessment of highly potent isatin-based small-molecules bearing 3-hydrazineyl-6-aryl-1,2,4-triazine moieties as potential c-MET targeting anticancer agents. Bioorganic chemistry · 27 May 2026 PMID 42202586
Immune Escape in Squamous Cancer (2)
  1. c-MET Inhibition Is Accompanied by PD-L1 Upregulation and Immunosuppression-Related Tumor Microenvironment Changes in Esophageal Squamous Cell Carcinoma, With Enhanced Antitumor Activity in Combination With Anti-PD-1 Therapy. Cancer medicine · 1 Nov 2026 PMID 42968226
  2. Exploring spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma. Oral and maxillofacial surgery · 16 Sept 2026 PMID 42747499

By study type

Clinical trials (2)
  1. Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial. PloS one · 8 Oct 2026 PMID 42848781
  2. EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 24 Aug 2026 PMID 42635595
Observational studies and case reports (1)
  1. Exploring spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma. Oral and maxillofacial surgery · 16 Sept 2026 PMID 42747499
Human data, design not indexed (1)
  1. Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer. The journal of pathology. Clinical research · 30 Sept 2026 PMID 42811483
Preclinical: animal, cell and lab studies (5)
  1. c-MET Inhibition Is Accompanied by PD-L1 Upregulation and Immunosuppression-Related Tumor Microenvironment Changes in Esophageal Squamous Cell Carcinoma, With Enhanced Antitumor Activity in Combination With Anti-PD-1 Therapy. Cancer medicine · 1 Nov 2026 PMID 42968226
  2. Thieno[2,3-d]pyrimidine scaffold optimization for synergistic c-Met/STAT3 blockade: Synthesis, structure-activity relationships, in vitro potency, and apoptotic pathways in colorectal cancer. Bioorganic chemistry · 21 Sept 2026 PMID 42767173
  3. Fast tumor accumulation and payload release of c-Met targeting aptamer-drug conjugate enables robust anti-tumor efficacy. Cell reports. Medicine · 1 Sept 2026 PMID 42679803
  4. New indolin-2-one and isoindoline-1,3-dione derivatives as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro, in vivo, and in silico evaluation. Bioorganic chemistry · 13 Jul 2026 PMID 42442295
  5. Design, synthesis, and bioactivity assessment of highly potent isatin-based small-molecules bearing 3-hydrazineyl-6-aryl-1,2,4-triazine moieties as potential c-MET targeting anticancer agents. Bioorganic chemistry · 27 May 2026 PMID 42202586
Unclassified: not yet indexed with MeSH (1)
  1. Optimizing Endosomal Escape for Effective Aptamer-Based Ubiquitin-Mediated Degradation of c-Met. ACS applied materials & interfaces · 18 Oct 2026 PMID 42891827